Fibro-Inflammatory Disease Sees Relief in IL-11 mAb Development

Soft tissue tumors are a broad group of neoplasms that involve the connective tissue of the body. Each year, over 13,000 people in the US are diagnosed with soft tissue sarcomas and over 5,000 people succumb to the malignancy. Because soft tissue sarcomas are very ambiguous and amorphous, many time sarcomas are classified as an uncertain type. Advances in immunohistochemistry, as well as the utility of novel markers such as TFE3, TLE1, MyoD1, and MUC4, have aided pathologists in classifying these soft tissue tumors. This discussion will cover the key facts and statistics about soft tissue tumors and what role IHC plays in these difficult diagnoses.

Cell-mediated immunotherapies are an emerging modality that can revolutionize cancer research as well as the study of the immune system. However, establishing standardization and scalability for necessary bioanalytics into product release practices are hampered by two major challenges

Maize is one of the most economically important crops globally and much effort has been spent generating the high quality B73 reference genome. However, the 10 chromosome, 2.3 gigabase (Gb) B73 reference genome was a substantial challenge due to the fact it is comprised of 85% transposable elements, 75% of which are long terminal repeat (LTR) retrotransposons that share high sequence similarity and form nested repeat structures. Ultralong Oxford Nanopore Technology (ONT) holds the promise of traversing the complex repeat structures of maize and enabling rapid sequencing of new breeding lines.

In this webinar, Dr. Jiahui Yang provides an overview of antibody discovery platforms and discusses how single B cell sorting can be used to generate functional monoclonal antibodies for a range of applications including disease diagnosis and therapeutics.